On World AIDS Day, just occurred on 1st December, the research community reflected on advances in HIV research and the ongoing challenges in patient care.
Among the biomarkers being explored, High Mobility Group Box 1 (HMGB1) has emerged as a growing player in understanding co-infections and complications associated with HIV.
HMGB1 in HIV-HBV co-infection:
A recent study highlights how higher HMGB1 levels correlate with liver fibrosis progression in individuals with HIV-HBV co-infection, despite suppressive antiretroviral therapy (ART). This underscores HMGB1’s role in driving inflammation and cellular damage, emphasizing the need for early and sustained ART.
Elevated HMGB1 likely stems from increased hepatocyte death and immune activation, especially in individuals with a low nadir CD4+ T-cell count.
HMGB1 in HIV-positive pregnancies:
During pregnancy, individuals on protease inhibitor (PI)-based ART regimens exhibit significantly higher HMGB1 levels. These levels are associated with increased systemic inflammation, potentially contributing to preterm deliveries and adverse pregnancy outcomes. Such findings highlight the inflammatory and immunomodulatory impact of HMGB1 in HIV-positive pregnancies.
Implications for HIV care:
HMGB1 serves as more than just a biomarker—it is a potential therapeutic target to mitigate inflammation-driven complications in HIV-related conditions. From liver fibrosis in co-infections to pregnancy-related risks, understanding HMGB1’s mechanisms can help refine treatment strategies and improve patient outcomes.
HMGBiotech Srl can provide comprehensive information to facilitate informed decision-making for researches with HMGB1.
Contact us for your pre-sales questions about HMGB1
Read the full articles about the studies:
https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(24)00089-6/fulltext
https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2023.1282291/full
